journal
https://read.qxmd.com/read/39031966/improved-patient-adherence-to-family-based-helicobacter-pylori-infection-control-and-management-strategy-in-central-china-and-its-influencing-factors
#1
JOURNAL ARTICLE
Xiao-Ting Li, Lu Xu, Chen Zhang, Ya-Bin Qi, Ruo-Bing Hu, Mohammed Awadh Abdun, Xue-Chun Yu, Kuan Li, Ting-Ting Liu, Jing Ma, Wei Xiao, Ling Lan, Xue-Mei Wang, Ming-Bo Cao, Jian Li, Shuang-Yin Han, Xiu-Ling Li, Song-Ze Ding
BACKGROUND: Patient adherence status to the newly introduced family-based Helicobacter pylori (H. pylori) infection control and management strategy remains unclear, so are its influencing factors. We aim to investigate family members' adherence and its influencing factors during the family-based H. pylori infection management practice for related disease prevention. MATERIALS AND METHODS: Based on our previously family-based H. pylori survey in 2021, 282 families including 772 individuals were followed up 2 years after the initial survey to compare if the investigation and education might improve family member's adherence...
2024: Helicobacter
https://read.qxmd.com/read/39021274/effect-of-lactobacillus-gasseri-bio6369-and-lacticaseibacillus-rhamnosus-bio5326-on-gastric-carcinogenesis-induced-by-helicobacter-pylori-infection
#2
JOURNAL ARTICLE
Marine Jauvain, Gorann Lepied, Lucie Bénéjat, Nathalie Roudier, Christelle Dussert, Philippe Lehours, Christine Varon, Emilie Bessède
BACKGROUND: Helicobacter pylori infection-associated gastric adenocarcinoma is influenced by various factors, including the digestive microbiota. Lactic acid bacteria role in digestive carcinogenesis has been discussed, and some Lactobacillaceae family species have been shown to act against H. pylori-induced inflammation and colonization. However, their effects on H. pylori-related carcinogenesis have not yet been studied. Lactobacillaceae family effects on the epithelial-to-mesenchymal transition (EMT), emergence of cells with cancer stem cell (CSC) properties and the pro-inflammatory response of gastric epithelial cells to H...
2024: Helicobacter
https://read.qxmd.com/read/39001634/boosting-the-anti-helicobacter-efficacy-of-azithromycin-through-natural-compounds-insights-from-in%C3%A2-vitro-in%C3%A2-vivo-histopathological-and-molecular-docking-investigations
#3
JOURNAL ARTICLE
Mahmoud M Bendary, Arwa R Elmanakhly, Farag M Mosallam, Noaf Abdullah N Alblwi, Rasha A Mosbah, Walaa A Alshareef, Heba M R M Selim, Majid Alhomrani, Abdulhakeem S Alamri, Nesreen A Safwat, Ahmed M E Hamdan, Rana Elshimy
BACKGROUND: Antimicrobial-resistant Helicobacter pylori (H. pylori) poses a significant public health concern, especially given the limited therapeutic options for azithromycin-resistant strains. Hence, there is a necessity for new studies to reconsider the use of azithromycin, which has diminished in effectiveness against numerous strains. Thus, we aimed to augment azithromycin's anti-Helicobacter properties by combining it with curcumin in different formulations, including curcumin in clove oil, curcumin nano-gold emulsion, and curcumin nanoemulsion...
2024: Helicobacter
https://read.qxmd.com/read/39001621/indications-of-helicobacter-pylori-eradication-treatment-and-its-influence-on-prescriptions-and-effectiveness-hp-eureg
#4
JOURNAL ARTICLE
Samuel J Martínez-Domínguez, Olga P Nyssen, Ángel Lanas, Enrique Alfaro, Laimas Jonaitis, Umud Mahmudov, Irina Voynovan, Babayeva Gülüstan, Luis Rodrigo, Giulia Fiorini, Ángeles Perez-Aisa, Javier Tejedor-Tejada, Bojan Tepes, Ludmila Vologzanina, Emin Mammadov, Frode Lerang, Quliyev Fərid Vidadi Oğlu, Natalia V Bakulina, Rustam Abdulkhakov, Ilchishina Tatiana, Thomas J Butler, Aiman Silkanovna Sarsenbaeva, Renate Bumane, Alfredo J Lucendo, Marco Romano, Luis Bujanda, Sayar R Abdulkhakov, Oleg Zaytsev, Manuel Pabón-Carrasco, Alma Keco-Huerga, Maja Denkovski, Jose M Huguet, Monica Perona, Óscar Núñez, Matteo Pavoni, Galyna Fadieienko, Sergey Alekseenko, Sinead M Smith, Luis Hernández, Juozas Kupcinskas, Dmitry S Bordin, Mārcis Leja, Antonio Gasbarrini, Oleksiy Gridnyev, Anna Cano-Català, Pablo Parra, Leticia Moreira, Francis Mégraud, Colm O'Morain, Javier P Gisbert
BACKGROUND: The influence of indications for Helicobacter pylori investigation on prescriptions and effectiveness is unknown. The aim of the study was to assess the impact of indications for H. pylori investigation on prescriptions, effectiveness, compliance, and tolerance. METHODS: International, prospective, non-interventional registry of the management of H. pylori infection by European gastroenterologists (Hp-EuReg). Treatment-näive patients registered from 2013 to 2023 at e-CRF AEG-REDCap were analyzed...
2024: Helicobacter
https://read.qxmd.com/read/38987862/antimicrobial-resistance-of-helicobacter-pylori-isolated-from-latin-american-children-and-adolescents-2008-2023-a-systematic-review
#5
JOURNAL ARTICLE
Camila Cabrera, Joaquín Torres, Carolina A Serrano, Paulina Gallardo, Vicente Orellana, Sergio George, Miguel O'Ryan, Yalda Lucero
BACKGROUND: Latin America has a high prevalence of Helicobacter pylori in children that may lead to peptic ulcer disease and eventually gastric cancer in adulthood. Successful eradication is hindered by rising antimicrobial resistance. We summarize H. pylori resistance rates in Latin American children from 2008 to 2023. MATERIAL AND METHODS: Systematic review following PRISMA guidelines and National Heart, Lung, and Blood Institute checklist to assess risk of bias (PROSPERO CRD42024517108) that included original cross-sectional observational studies reporting resistance to commonly used antibiotics in Latin American children and adolescents...
2024: Helicobacter
https://read.qxmd.com/read/38984746/eradication-therapy-for-helicobacter-pylori-infection-in-patients-receiving-hemodialysis-review
#6
REVIEW
Shu Sahara, Mitsushige Sugimoto, Masaki Murata, Eri Iwata, Takashi Kawai, Kazunari Murakami, Yoshio Yamaoka, Tadashi Shimoyama
Patients receiving hemodialysis (HD) often develop gastrointestinal diseases. Recently, although in general population, clinical guidelines for Helicobacter pylori have strongly recommended its eradication in patients to prevent gastric cancer, optimal eradication regimen and optimal dosage of drugs for patients receiving HD have not been established, due to possible incidence of adverse events. Some antimicrobial agents used in eradication therapy, particularly amoxicillin, can exacerbate renal dysfunction...
2024: Helicobacter
https://read.qxmd.com/read/38984721/risk-of-map-like-redness-development-after-eradication-therapy-for-helicobacter-pylori-infection
#7
JOURNAL ARTICLE
Sho Matsumoto, Mitsushige Sugimoto, Masakatsu Fukuzawa, Nana Uesugi, Eri Iwata, Yasuyuki Kagawa, Akira Madarame, Yohei Koyama, Takashi Morise, Kumiko Uchida, Hayato Yamaguchi, Shin Kono, Sakiko Naito, Takashi Kawai, Takao Itoi
BACKGROUND: Map-like redness is a newly identified endoscopic risk factor for gastric cancer in patients who received Helicobacter pylori eradication therapy. However, the incidence rate of map-like redness in patients who received eradication, and the risk factors for the development of map-like redness remain unclear. We hence aimed to investigate the incidence rate of map-like redness at 1-year post H. pylori eradication, and evaluated its associations with map-like redness and gastric cancer in relation with gastric condition...
2024: Helicobacter
https://read.qxmd.com/read/38984661/long-term-effects-of-fecal-microbiota-transplantation-on-gut-microbiota-after-helicobacter-pylori-eradication-with-bismuth-quadruple-therapy-a-randomized-controlled-trial
#8
RANDOMIZED CONTROLLED TRIAL
Jing-Tao Zhao, Yi Zhang, Xing-Wei Wang, Pei-Ying Zou, Zhe Zhao, Hao Mei, Yu-Xiang Liu, Na-Yun Su, Yang-Jie Zhu, Bin Wang, Yan-Ling Wei, Dong-Feng Chen, Chun-Hui Lan
BACKGROUND: Eradicating Helicobacter pylori infection by bismuth quadruple therapy (BQT) is effective. However, the effect of BQT and subsequent fecal microbiota transplant (FMT) on the gut microbiota is less known. MATERIALS AND METHODS: This prospective randomized controlled trial was conducted at a tertiary hospital in China from January 2019 to October 2020, with the primary endpoints the effect of BQT on the gut microbiota and the effect of FMT on the gut microbiota after bismuth quadruple therapy eradication therapy...
2024: Helicobacter
https://read.qxmd.com/read/38951739/integrin-linked-kinase-in-the-development-of-gastric-tumors-induced-by-helicobacter-pylori-regulation-and-prevention-potential
#9
JOURNAL ARTICLE
Boqing Li, Jing He, Ruiqing Zhang, Sisi Liu, Xiaolin Zhang, Zhiqin Li, Chunlei Ma, Wenke Wang, Yingzi Cui, Ying Zhang
BACKGROUND: Integrin-linked kinase (ILK) is crucial in solid tumors by regulating the Hippo-Yes-associated protein 1 (YAP) pathway. This study aimed to uncover how Helicobacter pylori influences ILK levels and its role in regulating YAP during H. pylori-induced gastric cancer. MATERIALS AND METHODS: GES-1 cells with stable Ilk knockdown and overexpression and a mouse carcinogenesis model for H. pylori infection were constructed. And ILK, the phosphorylated mammalian STE20-like protein kinase 1 (MST1), large tumor suppressor 1 (LATS1; S909, T1079), and YAP (S109, S127) were detected in cells, and mice by western blotting, as well as fluorescence intensity of YAP were assayed by immunofluorescence...
2024: Helicobacter
https://read.qxmd.com/read/38943311/helicobacter-pylori-infection-does-not-protect-against-allergic-diseases-evidence-from-a-pediatric-cohort-from-northern-sardinia-italy
#10
JOURNAL ARTICLE
Maria Pina Dore, Gianfranco Meloni, Ica Bassu, Giovanni Mario Pes
BACKGROUND: The "hygiene hypothesis" states that reduced exposure to microbial antigens due to an excessively hygienic environment can increase the risk of developing autoimmune diseases, including atopic disorders and asthma. In recent decades, there has been a progressive decline in the prevalence of numerous microorganisms following improved hygienic-sanitary conditions. More specifically, several studies reported an inverse association between the reduction in Helicobacter pylori infection and the rise of asthma and allergic disorders...
2024: Helicobacter
https://read.qxmd.com/read/38924222/the-interplay-between-helicobacter-pylori-and-suppressors-of-cytokine-signaling-socs-molecules-in-the-development-of-gastric-cancer-and-induction-of-immune-response
#11
REVIEW
Abdollah Jafarzadeh, Zahra Jafarzadeh, Maryam Nemati, Akihiko Yoshimura
Helicobacter pylori (H. pylori) colonizes the stomach and leads to the secretion of a vast range of cytokines by infiltrated leukocytes directing immune/inflammatory response against the bacterium. To regulate immune/inflammatory responses, suppressors of cytokine signaling (SOCS) proteins bind to multiple signaling components located downstream of cytokine receptors, such as Janus kinase (JAK), signal transducers and activators of transcription (STAT). Dysfunctional SOCS proteins in immune cells may facilitate the immune evasion of H...
2024: Helicobacter
https://read.qxmd.com/read/38923222/immunoinformatics-based-designing-of-novel-and-potent-multi-epitope-psa-d15-and-cag11-immunogens-for-helicobacter-pylori-immunodiagnostic-assay-development
#12
JOURNAL ARTICLE
Biniam Moges Eskeziyaw, Rebecca Waihenya, Naomi Maina, Samson Muuo Nzou
Helicobacter pylori (H. pylori) strain is the most genetically diverse pathogenic bacterium and now alarming serious human health concern ranging from chronic gastritis to gastric cancer and human death all over the world. Currently, the majority of commercially available diagnostic assays for H. pylori is a challenging task due to the heterogeneity of virulence factors in various geographical regions. In this concern, designing of universal multi-epitope immunogenic biomarker targeted for all H...
2024: Helicobacter
https://read.qxmd.com/read/38900537/low-dose-or-high-dose-amoxicillin-in-vonoprazan-based-dual-therapy-for-helicobacter-pylori-eradication-a-systematic-review-and-meta-analysis
#13
REVIEW
Kun-Ping Ju, Qing-Zhou Kong, Yue-Yue Li, Yan-Qing Li
BACKGROUND: The amoxicillin dose used in dual therapy to eradicate Helicobacter pylori varies across studies and the optimal amoxicillin dose for vonoprazan-based dual therapies remains unclear. We aimed to investigate the efficacy and safety of low- and high-dose amoxicillin in vonoprazan-amoxicillin dual therapy. MATERIALS AND METHODS: A comprehensive systematic review was conducted by searching databases from inception to October 2023. All trials that evaluated the effectiveness and safety of vonoprazan-amoxicillin dual therapy for eradicating H...
2024: Helicobacter
https://read.qxmd.com/read/38898622/global-primary-antibiotic-resistance-rate-of-helicobacter-pylori-in-recent-10%C3%A2-years-a-systematic-review-and-meta-analysis
#14
REVIEW
Yanhui Yu, Jing Xue, Fangbing Lin, Daming Liu, Wen Zhang, Shuying Ru, Feng Jiang
INTRODUCTION: Due to irregular antibiotic use, the rate of antibiotic resistance to Helicobacter pylori (H. pylori) is increasing and varies from region to region. Therefore, for the purpose of further clarifying the changes in antibiotic resistance rates nowadays, we conducted a systematic review and meta-analysis to update and assess the 10-year trend of primary H. pylori antibiotic resistance rate to the commonly prescribed antibiotics worldwide. MATERIALS AND METHODS: According to the PRISMA statement, we systematically searched electronic databases for studies that assessed rates of H...
2024: Helicobacter
https://read.qxmd.com/read/38884194/after-28%C3%A2-years-professor-david-y-graham-says-goodbye-and-helicobacter-welcomes-a-new-editor
#15
EDITORIAL
David Y Graham
No abstract text is available yet for this article.
2024: Helicobacter
https://read.qxmd.com/read/38874128/family-based-helicobacter-pylori-infection-control-and-management-strategy-and-screen-and-treat-strategy-are-highly-cost-effective-in-preventing-multiple-upper-gastrointestinal-diseases-in-chinese-population-at-national-level
#16
JOURNAL ARTICLE
Chen Zhang, Ya-Bin Qi, Ruo-Bing Hu, Lu Xu, Xiao-Ting Li, Jing Ma, Qiao-Qiao Shao, Mohammed Awadh Abdun, Ishtiaq Ur Rahman, Wen-Jun Shi, Fu-Qiang Li, Jian-Jie Yu, Ming-Kai Yuan, Qi Chen, Hong Lu, Song-Ze Ding
BACKGROUND: The overall benefits of the newly introduced family-based Helicobacter pylori (H. pylori) infection control and management (FBCM) and screen-and-treat strategies in preventing multiple upper gastrointestinal diseases at national level in China have not been explored. We investigate the cost-effectiveness of these strategies in the whole Chinese population. MATERIALS AND METHODS: Decision trees and Markov models of H. pylori infection-related non-ulcer dyspepsia (NUD), peptic ulcer disease (PUD), and gastric cancer (GC) were developed to simulate the cost-effectiveness of these strategies in the whole 494 million households in China...
2024: Helicobacter
https://read.qxmd.com/read/38873902/efficacy-of-tetracycline-three-times-daily-was-comparable-to-that-of-four-times-daily-for-helicobacter-pylori-rescue-treatment-a-multicenter-noninferiority-randomized-controlled-trial
#17
RANDOMIZED CONTROLLED TRIAL
Zhongxue Han, Qiumei Zhang, Iqtida Ahmed Mirza, Yuming Ding, Xueping Nan, Qing Zhao, Ruili Li, Lidong Xu, Ning Zhang, Miao Duan, Shuyan Zeng, Qingzhou Kong, Wenlin Zhang, Hui Wang, Xiaoqi Wu, Xiuli Zuo, Yanqing Li, Yueyue Li
BACKGROUND: The optimal dosage of tetracycline remains unclear for Helicobacter pylori eradication. Frequent dosing requirements may decrease patient adherence and increase the incidence of adverse events, potentially reducing treatment efficacy. This study aimed to compare the efficacy of different tetracycline dosages in rescue treatment for H. pylori infection. METHODS: A total of 406 patients needing H. pylori rescue treatment were enrolled. Patients were randomized into two groups and received bismuth-containing quadruple therapies as follows: esomeprazole 40 mg twice daily, bismuth 220 mg twice daily, amoxicillin 1000 mg twice daily, and tetracycline 500 mg either three (TET-T group) or four (TET-F group) times daily...
2024: Helicobacter
https://read.qxmd.com/read/38873839/helicobacter-pylori-caga-promotes-the-formation-of-gallstones-by-increasing-the-permeability-of-gallbladder-epithelial-cells
#18
JOURNAL ARTICLE
Jingjing Yu, Yuanhang He, Wenchao Yao, Tianming Liu, Xuxu Liu, Yi Zheng, Chenjun Hao, Dongbo Xue
BACKGROUND: The formation of gallstones is often accompanied by chronic inflammation, and the mechanisms underlying inflammation and stone formation are not fully understood. Our aim is to utilize single-cell transcriptomics, bulk transcriptomics, and microbiome data to explore key pathogenic bacteria that may contribute to chronic inflammation and gallstone formation, as well as their associated mechanisms. METHODS: scRNA-seq data from a gallstone mouse model were extracted from the Gene Expression Omnibus (GEO) database and analyzed using the FindCluster() package for cell clustering analysis...
2024: Helicobacter
https://read.qxmd.com/read/38867649/exploring-the-capacities-of-chatgpt-a-comprehensive-evaluation-of-its-accuracy-and-repeatability-in-addressing-helicobacter-pylori-related-queries
#19
JOURNAL ARTICLE
Yongkang Lai, Foqiang Liao, Jiulong Zhao, Chunping Zhu, Yi Hu, Zhaoshen Li
BACKGROUND: Educational initiatives on Helicobacter pylori (H. pylori) constitute a highly effective approach for preventing its infection and establishing standardized protocols for its eradication. ChatGPT, a large language model, is a potentially patient-friendly online tool capable of providing health-related knowledge. This study aims to assess the accuracy and repeatability of ChatGPT in responding to questions related to H. pylori. MATERIALS AND METHODS: Twenty-one common questions about H...
2024: Helicobacter
https://read.qxmd.com/read/38853394/fourteen-day-tegoprazan-amoxicillin-dual-therapy-as-the-first-line-treatment-of-helicobacter-pylori-infection-share2301-a-multicenter-noninferiority-randomized-clinical-trial
#20
RANDOMIZED CONTROLLED TRIAL
Qingzhou Kong, Iqtida Ahmed Mirza, Xiaoqian Zhang, Xiaohui Song, Xiaowei Li, Qiumei Zhang, Lidong Xu, Yuting Guo, Yanan Yu, Xiuli Zuo, Yanqing Li, Yueyue Li
BACKGROUND: Potassium-competitive acid blockers have demonstrated enormous potential in the eradication treatment of Helicobacter pylori infection, with tegoprazan being one of the representatives. The available data on the safety and efficacy of tegoprazan in dual therapy are limited. MATERIALS AND METHODS: The multicenter, noninferiority, randomized-controlled trial was conducted from May 2023 to March 2024. Treatment-naive subjects were randomly assigned (1:1) to enter either the tegoprazan-amoxicillin (TA) group (tegoprazan 50 mg twice daily and amoxicillin 750 mg four times daily) or the esomeprazole-amoxicillin (EA) group (esomeprazole 20 mg and amoxicillin 750 mg all four times daily), with a duration for 14 days...
2024: Helicobacter
journal
journal
32491
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.